Upgrade to SI Premium - Free Trial

Galmed Pharma (GLMD)

0.60 -0.02 (3.23%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

Form POS EX Galmed Pharmaceuticals June 8, 2026 8:36 AM - SEC Filing Form 424B3 Galmed Pharmaceuticals June 8, 2026 8:33 AM - SEC Filing Form 6-K Galmed Pharmaceuticals For: Jun 08 June 8, 2026 8:26 AM - SEC Filing Galmed to acquire Colospan for $4.5 million in medical device deal June 8, 2026 8:11 AM - StreetInsider Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market June 8, 2026 8:11 AM - PR NewsWire Form 6-K Galmed Pharmaceuticals For: Jun 02 June 2, 2026 7:58 AM - SEC Filing Galmed and Tissue Dynamics identify cardiac fibrosis pathway June 2, 2026 7:31 AM - StreetInsider Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis June 2, 2026 7:30 AM - PR NewsWire Form 6-K Galmed Pharmaceuticals For: May 14 May 14, 2026 7:52 AM - SEC Filing Galmed reports 500% bioavailability boost for oral aramchol formulation May 14, 2026 7:31 AM - StreetInsider Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 3 May 14, 2026 7:30 AM - PR NewsWire Form 6-K Galmed Pharmaceuticals For: May 06 May 6, 2026 7:47 AM - SEC Filing Tissue Dynamics partners with Galmed to develop cardiac fibrosis platform May 6, 2026 7:32 AM - StreetInsider Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics May 6, 2026 7:30 AM - PR NewsWire Form 6-K Galmed Pharmaceuticals For: Apr 14 April 14, 2026 7:42 AM - SEC Filing Galmed partners with Tel Aviv University to test brain cancer treatment April 14, 2026 7:32 AM - StreetInsider Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers April 14, 2026 7:30 AM - PR NewsWire Form 6-K Galmed Pharmaceuticals For: Apr 09 April 9, 2026 8:40 AM - SEC Filing Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol April 9, 2026 7:30 AM - PR NewsWire Form EFFECT Galmed Pharmaceuticals April 2, 2026 6:07 AM - SEC Filing Form POS AM Galmed Pharmaceuticals March 31, 2026 4:37 PM - SEC Filing Form 20-F Galmed Pharmaceuticals For: Dec 31 March 31, 2026 4:17 PM - SEC Filing Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 March 31, 2026 4:15 PM - PR NewsWire Full Article List